Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients
Blood · 2025
DOI: 10.1182/blood.2024028019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2025. Verfasst von Alastair L Smith und 17 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxfo…. Hauptthemen laut MEDLINE: Enhancer Elements, Genetic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Gene Expression Regulation, Leukemic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Genetic alterations alone cannot account for the diverse phenotypes of cancer cells. Even cancers with the same driver mutation show significant transcriptional heterogeneity and varied responses to therapy. However, the mechanisms underpinning this heterogeneity remain underexplored. Here, we find that novel enhancer usage is a common feature in acute lymphoblastic leukemia (ALL). In particular, KMT2A::AFF1 ALL, an aggressive leukemia with a poor prognosis and a low mutational burden, exhibits substantial transcriptional heterogeneity between individuals. Using single-cell multiome analysis and extensive chromatin profiling, we reveal that much transcriptional heterogeneity in KMT2A::AFF1 ALL is driven by novel enhancer usage. By generating high-resolution Micro Capture-C data in primary patient samples, we identify patient-specific enhancer activity at key oncogenes such as MEIS1 and RUNX2, driving high levels of expression of both oncogenes in a patient-specific manner. Overall, our data show that enhancer heterogeneity is highly prevalent in KMT2A::AFF1 ALL and may be a mechanism that drives transcriptional heterogeneity in cancer more generally.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
- Department of Paediatrics, University of Oxford, Oxford, United Kingdom.
- Dark Blue Therapeutics Ltd, Oxford, United Kingdom.
- Department of Laboratory Medicine, University of California, San Francisco, CA.
- Trinity College, University of Dublin, Dublin, Ireland.
- Systems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland.
ORCID-Profile: Alastair L Smith, Catherine Chahrour, Ana M Dopico-Fernandez, Natalina Elliott, Jonathan Bond, Irene Roberts, Ronald W Stam, Nicholas T Crump, James O J Davies, Anindita Roy, Thomas A Milne
Förderung
- Wellcome Trust
Zitieren
APA
Smith, A. L., Denny, N., Chahrour, C., Sharp, K., Arachi, M., Dopico-Fernandez, A. M., Elliott, N., Harman, J. R., Jackson, T., Geng, H., Smith, O., Bond, J., Roberts, I., Stam, R. W., Crump, N. T., Davies, J. O. J., Roy, A., & Milne, T. A. (2025). Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients. Blood. https://doi.org/10.1182/blood.2024028019
Vancouver
Smith AL, Denny N, Chahrour C, Sharp K, Arachi M, Dopico-Fernandez AM, et al. Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients. Blood. 2025. doi:10.1182/blood.2024028019
BibTeX
@article{Smith2025,
author = {Smith, Alastair L and Denny, Nicholas and Chahrour, Catherine and Sharp, Kim and Arachi, Marta and Dopico-Fernandez, Ana M and Elliott, Natalina and Harman, Joe R and Jackson, Thomas and Geng, Huimin and Smith, Owen and Bond, Jonathan and Roberts, Irene and Stam, Ronald W and Crump, Nicholas T and Davies, James O J and Roy, Anindita and Milne, Thomas A},
title = {Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients},
journal = {Blood},
year = {2025},
doi = {10.1182/blood.2024028019}
}
EUVIMED